A systematic review of salvage therapy to patients with metastatic colorectal cancer previously treated with fluorouracil, oxaliplatin and irinotecan +/- targeted therapy

Cancer Treatment Reviews

Volumn 40, Issue 6, 2014, Pages 701-715

  Nielsen, Dorte Lisbet ^a   Palshof, Jesper Andreas ^a   Larsen, Finn Ole ^a   Jensen, Benny Vittrup ^a   Pfeiffer, Per ^b  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b ODENSE UNIVERSITY HOSPITAL   (Denmark)

Author keywords

Chemotherapy; Colorectal cancer; Refractory; Salvage therapy; Targeted therapy

Indexed keywords

AFLIBERCEPT; BEVACIZUMAB; BIRINAPANT; BRIVANIB; CAPECITABINE; CARBOPLATIN; CETUXIMAB; CYCLOPHOSPHAMIDE; ERLOTINIB; EVEROLIMUS; FLUOROURACIL; GEMCITABINE; GIMERACIL PLUS OTERACIL POTASSIUM PLUS TEGAFUR; HISTONE DEACETYLASE INHIBITOR; IRINOTECAN; LINIFANIB; MITOMYCIN; N (6,7 DIHYDRO 6 OXO 5H DIBENZ[B,D]AZEPIN 7 YL) 2,2 DIMETHYL N' (2,2,3,3,3 PENTAFLUOROPROPYL)PROPANEDIAMIDE; OXALIPLATIN; PANITUMUMAB; PANOBINOSTAT; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; PROTEIN TYROSINE KINASE INHIBITOR; RALTITREXED; REGORAFENIB; SUNITINIB; TEMSIROLIMUS; THALIDOMIDE; UFT; UNINDEXED DRUG;

CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER SURVIVAL; DRUG EFFICACY; DRUG RECHALLENGE; HUMAN; METASTATIC COLORECTAL CANCER; MOLECULARLY TARGETED THERAPY; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); RETROSPECTIVE STUDY; REVIEW; SALVAGE THERAPY; SURVIVAL TIME; SYSTEMATIC REVIEW; SYSTEMIC THERAPY; WILD TYPE;

CHEMOTHERAPY; COLORECTAL CANCER; REFRACTORY; SALVAGE THERAPY; TARGETED THERAPY;

ALANINE; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; COLORECTAL NEOPLASMS; DATABASES, FACTUAL; FLUOROURACIL; HEPATIC ARTERY; HUMANS; INFUSIONS, INTRA-ARTERIAL; LIVER NEOPLASMS; MOLECULAR TARGETED THERAPY; ORGANOPLATINUM COMPOUNDS; PHENYLUREA COMPOUNDS; PUBMED; PYRIDINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; RETREATMENT; SALVAGE THERAPY; TREATMENT FAILURE; TRIAZINES;

EID: 84899945019     PISSN: 03057372     EISSN: 15321967     Source Type: Journal    
DOI: 10.1016/j.ctrv.2014.02.006     Document Type: Review

References (139)

1. Haggar F.A., Boushey R.P. Colorectal cancer epidemiology: incidence, mortality, survival, and risk factors. Clin Colon Rectal Surg 2009, 22:191-197.
2. de Gramont A., Vignoud J., Tournigand C., Louvet C., Andre T., Varette C., et al. Oxaliplatin with high-dose leucovorin and 5-fluorouracil 48-hour continuous infusion in pretreated metastatic colorectal cancer. Eur J Cancer 1997, 33:214-219.
3. Rothenberg M.L., Oza A.M., Bigelow R.H., Berlin J.D., Marshall J.L., Ramanathan R.K., et al. Superiority of oxaliplatin and fluorouracil-leucovorin compared with either therapy alone in patients with progressive colorectal cancer after irinotecan and fluorouracil-leucovorin: interim results of a phase III trial. J Clin Oncol 2003, 21:2059-2069.
4. Custodio A., Feliu J. Prognostic and predictive biomarkers for epidermal growth factor receptor-targeted therapy in colorectal cancer: beyond KRAS mutations. Crit Rev Oncol Hematol 2013, 85:45-81.
5. Douillard J.-Y., Siena S., Tabernero J., Burkes R.L., Barugel M.E., Humblet Y., et al. Overall survival (OS) analysis from PRIME: randomized phase III study of panitumumab (pmab) with FOLFOX4 for first-line metastatic colorectal cancer (mCRC). ASCO Meet Abstr 2013, 31:3620.
6. Yeung Y., Tebbutt N.C. Bevacizumab in colorectal cancer: current and future directions. Expert Rev Anticancer Ther 2012, 12:1263-1273.
7. Van Cutsem E., Tabernero J., Lakomy R., Prenen H., Prausova J., Macarulla T., et al. Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen. J Clin Oncol 2012, 30:3499-3506.
8. Grothey A., Van Cutsem E., Sobrero A., Siena S., Falcone A., Ychou M., et al. Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet 2013, 381:303-312.
9. Peeters M., Price T. Biologic therapies in the metastatic colorectal cancer treatment continuum-applying current evidence to clinical practice. Cancer Treat Rev 2012, 38:397-406.
10. Koopman M., Antonini N.F., Douma J., Wals J., Honkoop A.H., Erdkamp F.L., et al. Sequential versus combination chemotherapy with capecitabine, irinotecan, and oxaliplatin in advanced colorectal cancer (CAIRO): a phase III randomised controlled trial. Lancet 2007, 370:135-142.
11. Seymour M.T., Maughan T.S., Ledermann J.A., Topham C., James R., Gwyther S.J., et al. Different strategies of sequential and combination chemotherapy for patients with poor prognosis advanced colorectal cancer (MRC FOCUS): a randomised controlled trial. Lancet 2007, 370:143-152.
12. Ducreux M., Malka D., Mendiboure J., Etienne P.L., Texereau P., Auby D., et al. Sequential versus combination chemotherapy for the treatment of advanced colorectal cancer (FFCD 2000-05): an open-label, randomised, phase 3 trial. Lancet Oncol 2011, 12:1032-1044.
13. Hernandez-Aya L.F., Gonzalez-Angulo A.M. Targeting the phosphatidylinositol 3-kinase signaling pathway in breast cancer. Oncologist 2011, 16:404-414.
14. Chibaudel B., Tournigand C., Andre T., de Gramont A. Therapeutic strategy in unresectable metastatic colorectal cancer. Ther Adv Med Oncol 2012, 4:75-89.
15. Jonker D.J., O'Callaghan C.J., Karapetis C.S., Zalcberg J.R., Tu D., Au H.J., et al. Cetuximab for the treatment of colorectal cancer. N Engl J Med 2007, 357:2040-2048.
16. Rimassa L., Gullo G., Carnaghi C., Abbadessa G., Zuradelli M., Tronconi M.C., et al. Chemotherapy with mitomycin C and capecitabine in patients with advanced colorectal cancer pretreated with irinotecan and oxaliplatin. Tumori 2006, 92:285-289.
17. Scartozzi M., Falcone A., Pucci F., Braconi C., Pierantoni C., Cavanna L., et al. Capecitabine and mitomycin C may be an effective treatment option for third-line chemotherapy in advanced colorectal cancer. Tumori 2006, 92:384-388.
18. Ferrarotto R., Machado K., Mak M.P., Shah N., Takahashi T.K., Costa F.P., et al. A multicenter, multinational analysis of mitomycin C in refractory metastatic colorectal cancer. Eur J Cancer 2012, 48:820-826.
19. Vormittag L., Kornek G.V., Gruhsmann B., Lenauer A., Foger A., Depisch D., et al. UFT/leucovorin and mitomycin C as salvage treatment in patients with advanced colorectal cancer - a retrospective analysis. Anticancer Drugs 2007, 18:709-712.
20. Alkis N., Demirci U., Benekli M., Yilmaz U., Isikdogan A., Sevinc A., et al. Mitomycin-C in combination with fluoropyrimidines in the treatment of metastatic colorectal cancer after oxaliplatin and irinotecan failure. J BUON 2011, 16:80-83.
21. Gubanski M., Naucler G., Almerud A., Lidestahl A., Lind P.A. Capecitabine as third line therapy in patients with advanced colorectal cancer. Acta Oncol 2005, 44:236-239.
22. Lee S., Kwon H.-C., Kim S.-H., Oh S.Y., Lee J.H., Yoon H.-H., et al. Capecitabine monotherapy and the clinical significance of neutrophil-lymphocyte ratio versus platelet-lymphocyte ratio in patients with metastatic colorectal cancer. ASCO Meet Abstr 2012, 30:660.
23. Yasui H., Yoshino T., Boku N., Onozawa Y., Hironaka S., Fukutomi A., et al. Retrospective analysis of S-1 monotherapy in patients with metastatic colorectal cancer after failure to fluoropyrimidine and irinotecan or to fluoropyrimidine, irinotecan and oxaliplatin. Jpn J Clin Oncol 2009, 39:315-320.
24. Lee D.J., Lee J., Lee H.Y., Lim T., Lee S.J., Yi S.Y., et al. Salvage S-1 monotherapy in metastatic colorectal cancer patients who failed irinotecan-based or oxaliplatin-based chemotherapy. Med Oncol 2011, 28(Suppl. 1):S291-S294.
25. Salgado M., Reboredo M., Medina A., Quintero G., Pellon M.L., Romero Reinoso C., et al. Effectiveness of gemcitabine and capecitabine in advanced colorectal cancer patients: a retrospective analysis. ASCO Meet Abstr 2012, 30:649.
26. Solis Hernandez M.D.P., Jimenez P., Faez Garcia L., Alvarez Fernandez C., Perez Arnillas Q., Rodriguez Rubi D.J., et al. Biweekly gemcitabine and capecitabine in heavily pretreated patients with metastatic colorectal cancer (mCRC). ASCO Meet Abstr 2013, 31:e14617.
27. Kim S. Carboplatin plus fluorouracil (CF) as salvage treatment after failure of standard chemotherapy in patients with metastatic colorectal cancer. Ann Oncol 2013, 24:iv102-iv103.
28. Santini D., Vincenzi B., La Cesa A., Caricato M., Schiavon G., Spalletta B., et al. Continuous infusion of oxaliplatin plus chronomodulated capecitabine in 5-fluorouracil- and irinotecan-resistant advanced colorectal cancer patients. Oncology 2005, 69:27-34.
29. Townsend A.R., Bishnoi S., Broadbridge V., Beeke C., Karapetis C.S., Jain K., et al. Rechallenge with oxaliplatin and fluoropyrimidine for metastatic colorectal carcinoma after prior therapy. Am J Clin Oncol 2013, 36:49-52.
30. Lim D.H., Park Y.S., Park B.B., Ji S.H., Lee J., Park K.W., et al. Mitomycin-C and capecitabine as third-line chemotherapy in patients with advanced colorectal cancer: a phase II study. Cancer Chemother Pharmacol 2005, 56:10-14.
31. Francois E., Smith D., Dahan L., Michel C., Perrier H., Mari V., et al. Uracil-tegafur/leucovorin and mitomycin C salvage therapy in patients with advanced colorectal cancer: a phase II study. J Chemother 2012, 24:207-211.
32. Michalaki V., Gennatas S., Gennatas C., Mitomycin C. UFT/leucovorin as salvage treatment in patients with advanced colorectal cancer. J BUON 2010, 15:270-273.
33. Rosati G., Rossi A., Germano D., Reggiardo G., Manzione L. Raltitrexed and mitomycin-C as third-line chemotherapy for colorectal cancer after combination regimens including 5-fluorouracil, irinotecan and oxaliplatin: a phase II study. Anticancer Res 2003, 23:2981-2985.
34. Ardavanis A.S., Ioannidis G.N., Orphanos G.S., Rigatos G.A. Salvage treatment with single-agent capecitabine in patients with heavily pretreated advanced colorectal cancer. Anticancer Res 2006, 26:1669-1672.
35. Marmorino F., Cremolini C., Loupakis F., Salvatore L., Schirripa M., Antoniotti C., et al. Metronomic capecitabine (cape) and cyclophosphamide (CTX) for refractory metastatic colorectal cancer (mCRC): results of a phase II trial. ASCO Meeting Abstracts 2013, 31:e14577.
36. Jeung H.C., Rha S.Y., Cho B.C., Yoo N.C., Roh J.K., Roh W.J., et al. A phase II trial of S-1 monotherapy in metastatic colorectal cancer after failure of irinotecan- and oxaliplatin-containing regimens. Br J Cancer 2006, 95:1637-1641.
37. Sym S.J., Hong J., Ahn H.K., Park J., Cho E.K., Lee J.H., et al. A phase II trial of salvage treatment with gemcitabine and S-1 combination in heavily pretreated patients with metastatic colorectal cancer. ASCO Meet Abstr 2013, 31:3595.
38. Bitossi R., Sculli C.M., Tampellini M., Alabiso I., Brizzi M.P., Ferrero A., et al. Gemcitabine and protracted 5-fluorouracil infusion as third-line chemotherapy in refractory colorectal cancer patients. Anticancer Res 2008, 28:3055-3060.
39. Senzer N.N., LoRusso P., Martin L.P., Schilder R.J., Amaravadi R.K., Papadopoulos K.P., et al. Phase II clinical activity and tolerability of the SMAC-mimetic birinapant (TL32711) plus irinotecan in irinotecan-relapsed/refractory metastatic colorectal cancer. ASCO Meet Abstr 2013, 31:3621.
40. Yoshino T., Mizunuma N., Yamazaki K., Nishina T., Komatsu Y., Baba H., et al. TAS-102 monotherapy for pretreated metastatic colorectal cancer: a double-blind, randomised, placebo-controlled phase 2 trial. Lancet Oncol 2012, 13:993-1001.
41. Emura T., Murakami Y., Nakagawa F., Fukushima M., Kitazato K. A novel antimetabolite, TAS-102 retains its effect on FU-related resistant cancer cells. Int J Mol Med 2004, 13:545-549.
42. Nishiofuku H., Tanaka T., Aramaki T., Boku N., Inaba Y., Sato Y., et al. Hepatic arterial infusion of 5-fluorouracil for patients with liver metastases from colorectal cancer refractory to standard systemic chemotherapy: a multicenter, retrospective analysis. Clin Colorectal Cancer 2010, 9:305-310.
43. Khouri C., Guiu B., Cercueil J.P., Chauffert B., Ladoire S., Ghiringhelli F. Raltitrexed and oxaliplatin hepatic arterial infusion for advanced colorectal cancer: a retrospective study. Anticancer Drugs 2010, 21:656-661.
44. Bouchahda M., Adam R., Giacchetti S., Castaing D., Brezault-Bonnet C., Hauteville D., et al. Rescue chemotherapy using multidrug chronomodulated hepatic arterial infusion for patients with heavily pretreated metastatic colorectal cancer. Cancer 2009, 115:4990-4999.
45. Hong K., McBride J.D., Georgiades C.S., Reyes D.K., Herman J.M., Kamel I.R., et al. Salvage therapy for liver-dominant colorectal metastatic adenocarcinoma: comparison between transcatheter arterial chemoembolization versus yttrium-90 radioembolization. J Vasc Interv Radiol 2009, 20:360-367.
46. Ducreux M., Innominato P.F., Hebbar M., Smith D.M., Lepere C., Focan C.N.J., et al. Hepatic artery infusion (HAI) of irinotecan, 5-fluorouracil, and oxaliplatin plus intravenous cetuximab (Cet) (Optiliv) after failure on one versus two or three chemotherapy protocols in patients (pts) with unresectable liver metastases from wt KRAS colorectal cancer (LM-CRC) (European phase II clinical trial NCT00852228). ASCO Meet Abstr 2013, 31:3599.
47. Martin R.C., Joshi J., Robbins K., Tomalty D., Bosnjakovik P., Derner M., et al. Hepatic intra-arterial injection of drug-eluting bead, irinotecan (DEBIRI) in unresectable colorectal liver metastases refractory to systemic chemotherapy: results of multi-institutional study. Ann Surg Oncol 2011, 18:192-198.
48. Kang B.W., Kim T.W., Lee J.L., Ryu M.H., Chang H.M., Yu C.S., et al. Bevacizumab plus FOLFIRI or FOLFOX as third-line or later treatment in patients with metastatic colorectal cancer after failure of 5-fluorouracil, irinotecan, and oxaliplatin: a retrospective analysis. Med Oncol 2009, 26:32-37.
49. Geva R., Vecchione L., Tejpar S., Piessevaux H., Van Cutsem E., Prenen H. Bevacizumab plus chemotherapy as salvage treatment in chemorefractory patients with metastatic colorectal cancer. Onco Targets Ther 2013, 6:53-58.
50. Sogabe S., Komatsu Y., Yuki S., Kusumi T., Hatanaka K., Nakamura M., et al. Retrospective cohort study on the safety and efficacy of bevacizumab with chemotherapy for metastatic colorectal cancer patients: the HGCSG0801 study. Jpn J Clin Oncol 2011, 41:490-497.
51. Larsen F.O., Boisen M.K., Fromm A.L., Jensen B.V. Capecitabine and bevacizumab in heavily pre-treated patients with advanced colorectal cancer. Acta Oncol 2012, 51:231-233.
52. Chen H.X., Mooney M., Boron M., Vena D., Mosby K., Grochow L., et al. Phase II multicenter trial of bevacizumab plus fluorouracil and leucovorin in patients with advanced refractory colorectal cancer: an NCI Treatment Referral Center Trial TRC-0301. J Clin Oncol 2006, 24:3354-3360.
53. Vincenzi B., Santini D., Russo A., Spoto C., Venditti O., Gasparro S., et al. Bevacizumab in association with de Gramont 5-fluorouracil/folinic acid in patients with oxaliplatin-, irinotecan-, and cetuximab-refractory colorectal cancer: a single-center phase 2 trial. Cancer 2009, 115:4849-4856.
54. Takagane A., Miyake Y., Kobayashi K., Nagata N., Sato A., Ogata Y., et al. A phase II study on third-line chemotherapy combined bevacizumab with S-1 for metastatic colorectal cancer with mutated KRAS: SAVIOR study. ASCO Meet Abstr 2013, 31:552.
55. Tang P.A., Cohen S.J., Kollmannsberger C., Bjarnason G., Virik K., MacKenzie M.J., et al. Phase II clinical and pharmacokinetic study of aflibercept in patients with previously treated metastatic colorectal cancer. Clin Cancer Res 2012, 18:6023-6031.
56. Saltz L.B., Rosen L.S., Marshall J.L., Belt R.J., Hurwitz H.I., Eckhardt S.G., et al. Phase II trial of sunitinib in patients with metastatic colorectal cancer after failure of standard therapy. J Clin Oncol 2007, 25:4793-4799.
57. Chan E., Ayers G.D., Goff L., McClanahan P., Holloway M., Ciomber K., et al. Phase II study of linifanib in KRAS mutated metastatic refractory colorectal cancer. Eur J Cancer 2013, 49:S549.
58. McCollum A.D., Wu B., Clark J.W., Kulke M.H., Enzinger P.C., Ryan D.P., et al. The combination of capecitabine and thalidomide in previously treated, refractory metastatic colorectal cancer. Am J Clin Oncol 2006, 29:40-44.
59. Holash J., Davis S., Papadopoulos N., Croll S.D., Ho L., Russell M., et al. VEGF-Trap: a VEGF blocker with potent antitumor effects. Proc Natl Acad Sci USA 2002, 99:11393-11398.
60. Carrato A., Swieboda-Sadlej A., Staszewska-Skurczynska M., Lim R., Roman L., Shparyk Y., et al. Fluorouracil, leucovorin, and irinotecan plus either sunitinib or placebo in metastatic colorectal cancer: a randomized Phase III Trial. J Clin Oncol 2013, 31:1341-1347.
61. Ishiguro M., Watanabe T., Yamaguchi K., Satoh T., Ito H., Seriu T., et al. A Japanese post-marketing surveillance of cetuximab (Erbitux(R)) in patients with metastatic colorectal cancer. Jpn J Clin Oncol 2012, 42:287-294.
62. Gebbia V., Del Prete S., Borsellino N., Ferrau F., Tralongo P., Verderame F., et al. Efficacy and safety of cetuximab/irinotecan in chemotherapy-refractory metastatic colorectal adenocarcinomas: a clinical practice setting, multicenter experience. Clin Colorectal Cancer 2006, 5:422-428.
63. Pfeiffer P., Nielsen D., Yilmaz M., Iversen A., Vejlo C., Jensen B.V. Cetuximab and irinotecan as third line therapy in patients with advanced colorectal cancer after failure of irinotecan, oxaliplatin and 5-fluorouracil. Acta Oncol 2007, 46:697-701.
64. Adam R., Aloia T., Levi F., Wicherts D.A., de Haas R.J., Paule B., et al. Hepatic resection after rescue cetuximab treatment for colorectal liver metastases previously refractory to conventional systemic therapy. J Clin Oncol 2007, 25:4593-4602.
65. Pfeiffer P., Nielsen D., Bjerregaard J., Qvortrup C., Yilmaz M., Jensen B. Biweekly cetuximab and irinotecan as third-line therapy in patients with advanced colorectal cancer after failure to irinotecan, oxaliplatin and 5-fluorouracil. Ann Oncol 2008, 19:1141-1145.
66. Bouchahda M., Macarulla T., Liedo G., Levi F., Elez M.E., Paule B., et al. Feasibility of cetuximab given with a simplified schedule every 2 weeks in advanced colorectal cancer: a multicenter, retrospective analysis. Med Oncol 2011, 28(Suppl 1):S253-S258.
67. Levi F., Karaboue A., Gorden L., Innominato P.F., Saffroy R., Giacchetti S., et al. Cetuximab and circadian chronomodulated chemotherapy as salvage treatment for metastatic colorectal cancer (mCRC): safety, efficacy and improved secondary surgical resectability. Cancer Chemother Pharmacol 2011, 67:339-348.
68. Lam K., Lee V., Choi C., Sze H., Kwok R., Shum B., et al. Cetuximab beyond progression in KRAS wild-type metastatic colorectal cancer. Ann Oncol 2013, 24:iv108.
69. Saif M.W., Kaley K., Chu E., Copur M.S. Safety and efficacy of panitumumab therapy after progression with cetuximab: experience at two institutions. Clin Colorectal Cancer 2010, 9:315-318.
70. Power D.G., Shah M.A., Asmis T.R., Garcia J.J., Kemeny N.E. Safety and efficacy of panitumumab following cetuximab: retrospective review of the Memorial Sloan-Kettering experience. Invest New Drugs 2010, 28:353-360.
71. Sonoda H., Mekata E., Shimizu T., Endo Y., Tani T. Safety and efficacy of panitumumab therapy after metastatic colorectal cancer progression with cetuximab: experience at a single Japanese institution. Oncol Lett 2013, 5:1331-1334.
72. Kobayashi Y., Fukushima H., Sasaki T., Yuki S., Okuda H., Kusumi T., et al. Retrospective cohort study on the safety and efficacy of panitumumab for patients with metastatic colorectal cancer: the HGCSG1002 study-analysis of after cetuximab refractory. ASCO Meet Abstr 2013, 31:541.
73. Watanabe T., Shinozaki E., Kijima S., Ohhara Y., Kuboki Y., Takagi K., et al. Does panitumumab have a clinical benefit in cetuximab-refractory KRAS wild-type metastatic colorectal cancer?. ASCO Meet Abstr 2012, 30:654.
74. Metges J., Ramée J., Dupuis O., Deguiral P., Boucher E., Cojocarasu O., et al. PANERB study: which category of patients, suffering from metastatic colorectal cancer, can benefit from panitumumab treatment after cetuximab-based regimen failure?. Ann Oncol 2012, 23:ix196.
75. Wilke H., Glynne-Jones R., Thaler J., Adenis A., Preusser P., Aguilar E.A., et al. Cetuximab plus irinotecan in heavily pretreated metastatic colorectal cancer progressing on irinotecan: MABEL Study. J Clin Oncol 2008, 26:5335-5343.
76. Spindler K.L., Pallisgaard N., Lindebjerg J., Frifeldt S.K., Jakobsen A. EGFR related mutational status and association to clinical outcome of third-line cetuximab-irinotecan in metastatic colorectal cancer. BMC Cancer 2011, 11:107.
77. Roca J.M., Alonso V., Pericay C., Escudero P., Salud A., Losa F., et al. Cetuximab given every 2 weeks plus irinotecan is an active and safe option for previously treated patients with metastatic colorectal cancer. Chemotherapy 2010, 56:142-146.
78. Lenz H.J., Van Cutsem E., Khambata-Ford S., Mayer R.J., Gold P., Stella P., et al. Multicenter phase II and translational study of cetuximab in metastatic colorectal carcinoma refractory to irinotecan, oxaliplatin, and fluoropyrimidines. J Clin Oncol 2006, 24:4914-4921.
79. Gamucci T., Nelli F., Cianci G., Grassi G., Moscetti L., Sperduti I., et al. A phase II study of cetuximab/irinotecan in patients with heavily pretreated metastatic colorectal cancer: predictive value of early specific toxicities. Clin Colorectal Cancer 2008, 7:273-279.
80. Jensen B.V., Schou J.V., Johannesen H.H., Christensen I.J., Nielsen D., Johansen J.S., et al. Cetuximab every second week with irinotecan in patients with metastatic colorectal cancer refractory to 5-FU, oxaliplatin, and irinotecan: KRAS mutation status and efficacy. ASCO Meet Abstr 2010, 28:3573.
81. Santini D., Vincenzi B., Addeo R., Garufi C., Masi G., Scartozzi M., et al. Cetuximab rechallenge in metastatic colorectal cancer patients: how to come away from acquired resistance?. Ann Oncol 2012, 23:2313-2318.
82. Van Cutsem E., Tejpar S., Vanbeckevoort D., Peeters M., Humblet Y., Gelderblom H., et al. Intrapatient cetuximab dose escalation in metastatic colorectal cancer according to the grade of early skin reactions: the randomized EVEREST study. J Clin Oncol 2012, 30:2861-2868.
83. Van Cutsem E., Siena S., Humblet Y., Canon J.L., Maurel J., Bajetta E., et al. An open-label, single-arm study assessing safety and efficacy of panitumumab in patients with metastatic colorectal cancer refractory to standard chemotherapy. Ann Oncol 2008, 19:92-98.
84. Hecht J.R., Patnaik A., Berlin J., Venook A., Malik I., Tchekmedyian S., et al. Panitumumab monotherapy in patients with previously treated metastatic colorectal cancer. Cancer 2007, 110:980-988.
85. Wadlow R.C., Hezel A.F., Abrams T.A., Blaszkowsky L.S., Fuchs C.S., Kulke M.H., et al. Panitumumab in patients with KRAS wild-type colorectal cancer after progression on cetuximab. Oncologist 2012, 17:14.
86. Cunningham D., Humblet Y., Siena S., Khayat D., Bleiberg H., Santoro A., et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 2004, 351:337-345.
87. Van Cutsem E., Peeters M., Siena S., Humblet Y., Hendlisz A., Neyns B., et al. Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. J Clin Oncol 2007, 25:1658-1664.
88. Linardou H., Dahabreh I.J., Kanaloupiti D., Siannis F., Bafaloukos D., Kosmidis P., et al. Assessment of somatic k-RAS mutations as a mechanism associated with resistance to EGFR-targeted agents: a systematic review and meta-analysis of studies in advanced non-small-cell lung cancer and metastatic colorectal cancer. Lancet Oncol 2008, 9:962-972.
89. De Roock W., Claes B., Bernasconi D., De Schutter J., Biesmans B., Fountzilas G., et al. Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. Lancet Oncol 2010, 11:753-762.
90. Tejpar S., Lenz H.-J., Kohne C.-H., Heinemann V., Ciardiello F., Esser R., et al. Effect of KRAS and NRAS mutations on treatment outcomes in patients with metastatic colorectal cancer (mCRC) treated first-line with cetuximab plus FOLFOX4: New results from the OPUS study. ASCO Meet Abstr 2014, 32:LBA444.
91. Karapetis C.S., Khambata-Ford S., Jonker D.J., O'Callaghan C.J., Tu D., Tebbutt N.C., et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med 2008, 359:1757-1765.
92. Au H.J., Karapetis C.S., O'Callaghan C.J., Tu D., Moore M.J., Zalcberg J.R., et al. Health-related quality of life in patients with advanced colorectal cancer treated with cetuximab: overall and KRAS-specific results of the NCIC CTG and AGITG CO.17 trial. J Clin Oncol 2009, 27:1822-1828.
93. Polk A., Vaage-Nilsen M., Vistisen K., Nielsen D.L. Cardiotoxicity in cancer patients treated with 5-fluorouracil or capecitabine: a systematic review of incidence, manifestations and predisposing factors. Cancer Treat Rev 2013, 39:974-984.
94. Tabernero J., Pfeiffer P., Cervantes A. Administration of cetuximab every 2 weeks in the treatment of metastatic colorectal cancer: an effective, more convenient alternative to weekly administration?. Oncologist 2008, 13:113-119.
95. Brodowicz T., Ciuleanu T.E., Radosavljevic D., Shacham-Shmueli E., Vrbanec D., Plate S., et al. FOLFOX4 plus cetuximab administered weekly or every second week in the first-line treatment of patients with KRAS wild-type metastatic colorectal cancer: a randomized phase II CECOG study. Ann Oncol 2013, 24:1769-1777.
96. Andre T., Blons H., Mabro M., Chibaudel B., Bachet J.B., Tournigand C., et al. Panitumumab combined with irinotecan for patients with KRAS wild-type metastatic colorectal cancer refractory to standard chemotherapy: a GERCOR efficacy, tolerance, and translational molecular study. Ann Oncol 2013, 24:412-419.
97. Montagut C., Dalmases A., Bellosillo B., Crespo M., Pairet S., Iglesias M., et al. Identification of a mutation in the extracellular domain of the Epidermal Growth Factor Receptor conferring cetuximab resistance in colorectal cancer. Nat Med 2012, 18:221-223.
98. Sono K., Yamada A., Yoshimatsu Y., Takada N., Suzuki Y. Factors associated with the loss of response to infliximab in patients with Crohn's disease. Cytokine 2012, 59:410-416.
99. Larsen F.O., Pfeiffer P., Nielsen D., Skougaard K., Qvortrup C., Vistisen K., et al. Bevacizumab in combination with cetuximab and irinotecan after failure of cetuximab and irinotecan in patients with metastatic colorectal cancer. Acta Oncol 2011, 50:574-577.
100. Qvortrup C., Jensen B.V., Jorgensen T.L., Nielsen D., Bjerregaard J.K., Pfeiffer P. Addition of sunitinib to cetuximab and irinotecan in patients with heavily pre-treated advanced colorectal cancer. Acta Oncol 2010, 49:833-836.
101. Weickhardt A.J., Price T.J., Chong G., Gebski V., Pavlakis N., Johns T.G., et al. Dual targeting of the epidermal growth factor receptor using the combination of cetuximab and erlotinib: preclinical evaluation and results of the phase II DUX study in chemotherapy-refractory, advanced colorectal cancer. J Clin Oncol 2012, 30:1505-1512.
102. Altomare I., Bendell J.C., Bullock K.E., Uronis H.E., Morse M.A., Hsu S.D., et al. A phase II trial of bevacizumab plus everolimus for patients with refractory metastatic colorectal cancer. Oncologist 2011, 16:1131-1137.
103. Wolpin B.M., Ng K., Zhu A.X., Abrams T., Enzinger P.C., McCleary N.J., et al. Multicenter Phase II study of Tivozanib (AV-951) and Everolimus (RAD001) for patients with refractory, metastatic colorectal cancer. Oncologist 2013, 18:377-378.
104. Saltz L.B., Lenz H.J., Kindler H.L., Hochster H.S., Wadler S., Hoff P.M., et al. Randomized phase II trial of cetuximab, bevacizumab, and irinotecan compared with cetuximab and bevacizumab alone in irinotecan-refractory colorectal cancer: the BOND-2 study. J Clin Oncol 2007, 25:4557-4561.
105. Siu L.L., Shapiro J.D., Jonker D.J., Karapetis C.S., Zalcberg J.R., Simes J., et al. Phase III randomized, placebo-controlled study of cetuximab plus brivanib alaninate versus cetuximab plus placebo in patients with metastatic, chemotherapy-refractory, wild-type K-RAS colorectal carcinoma: the NCIC clinical trials group and AGITG CO.20 trial. J Clin Oncol 2013, 31:2477-2484.
106. Tol J., Koopman M., Cats A., Rodenburg C.J., Creemers G.J., Schrama J.G., et al. Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer. N Engl J Med 2009, 360:563-572.
107. Hecht J.R., Mitchell E., Chidiac T., Scroggin C., Hagenstad C., Spigel D., et al. A randomized phase IIIB trial of chemotherapy, bevacizumab, and panitumumab compared with chemotherapy and bevacizumab alone for metastatic colorectal cancer. J Clin Oncol 2009, 27:672-680.
108. Siu L.L., Shapiro J.D., Jonker D.J., Karapetis C.S., Zalcberg J.R., Simes J., et al. Phase III randomized trial of cetuximab (CET) plus either brivanib alaninate (BRIV) or placebo in patients (pts) with metastatic (MET) chemotherapy refractory K-RAS wild-type (WT) colorectal carcinoma (CRC): The NCIC clinical trials group and AGITG CO.20 trial. ASCO Meet Abstr 2012, 30:386.
109. Altomare I., Hurwitz H. Everolimus in colorectal cancer. Expert Opin Pharmacother 2013, 14:505-513.
110. Spindler K.L., Sorensen M.M., Pallisgaard N., Andersen R.F., Havelund B.M., Ploen J., et al. Phase II trial of temsirolimus alone and in combination with irinotecan for KRAS mutant metastatic colorectal cancer: outcome and results of KRAS mutational analysis in plasma. Acta Oncol 2013, 52:963-970.
111. Gold P.J., Smith D.A., Iriarte D., Boatman B., Kaplan H.G. Phase II trial of panobinostat (LBH589) in patients (pts) with refractory metastatic colorectal cancer (MCRC). ASCO Meet Abstr 2012, 30:582.
112. Strosberg J.R., Yeatman T., Weber J., Coppola D., Schell M.J., Han G., et al. A phase II study of RO4929097 in metastatic colorectal cancer. Eur J Cancer 2012, 48:997-1003.
113. Bendell J.C., Nemunaitis J., Vukelja S.J., Hagenstad C., Campos L.T., Hermann R.C., et al. Randomized placebo-controlled phase II trial of perifosine plus capecitabine as second- or third-line therapy in patients with metastatic colorectal cancer. J Clin Oncol 2011, 29:4394-4400.
114. Bendell J.C., Ervin T.J., Senzer N.N., Richards D.A., Firdaus I., Lockhart A.C., et al. Results of the X-PECT study: A phase III randomized double-blind, placebo-controlled study of perifosine plus capecitabine (P-CAP) versus placebo plus capecitabine (CAP) in patients (pts) with refractory metastatic colorectal cancer (mCRC). ASCO Meet Abstr 2012, 30:LBA3501.
115. van Blitterswijk W.J., Verheij M. Anticancer mechanisms and clinical application of alkylphospholipids. Biochim Biophys Acta 2013, 1831:663-674.
116. Momota H., Nerio E., Holland E.C. Perifosine inhibits multiple signaling pathways in glial progenitors and cooperates with temozolomide to arrest cell proliferation in gliomas in vivo. Cancer Res 2005, 65:7429-7435.
117. Petrelli F., Borgonovo K., Cabiddu M., Ghilardi M., Lonati V., Maspero F., et al. FOLFIRI-Bevacizumab as first-line chemotherapy in 3500 patients with advanced colorectal cancer: a pooled analysis of 29 published trials. Clin Colorectal Cancer 2013, 12:145-151.
118. Schmoll H.J., Van Cutsem E., Stein A., Valentini V., Glimelius B., Haustermans K., et al. ESMO Consensus Guidelines for management of patients with colon and rectal cancer. a personalized approach to clinical decision making. Ann Oncol 2012, 23:2479-2516.
119. Van Cutsem E., Nordlinger B., Cervantes A., Group EGW Advanced colorectal cancer: ESMO clinical practice guidelines for treatment. Ann Oncol 2010, 21(Suppl. 5):v93-v97.
120. Grothey A., Sargent D., Goldberg R.M., Schmoll H.J. Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment. J Clin Oncol 2004, 22:1209-1214.
121. Haller D.G., Cassidy J., Clarke S.J., Cunningham D., Van Cutsem E., Hoff P.M., et al. Potential regional differences for the tolerability profiles of fluoropyrimidines. J Clin Oncol 2008, 26:2118-2123.
122. Eikesdal H.P., Kalluri R. Drug resistance associated with antiangiogenesis therapy. Semin Cancer Biol 2009, 19:310-317.
123. Schneider B.P., Wang M., Radovich M., Sledge G.W., Badve S., Thor A., et al. Association of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 genetic polymorphisms with outcome in a trial of paclitaxel compared with paclitaxel plus bevacizumab in advanced breast cancer: ECOG 2100. J Clin Oncol 2008, 26:4672-4678.
124. Miles D.W., de Haas S.L., Dirix L.Y., Romieu G., Chan A., Pivot X., et al. Biomarker results from the AVADO phase 3 trial of first-line bevacizumab plus docetaxel for HER2-negative metastatic breast cancer. Br J Cancer 2013, 108:1052-1060.
125. Van Cutsem E., de Haas S., Kang Y.K., Ohtsu A., Tebbutt N.C., Ming Xu, et al. Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a biomarker evaluation from the AVAGAST randomized phase III trial. J Clin Oncol 2012, 30:2119-2127.
126. Vale C.L., Tierney J.F., Fisher D., Adams R.A., Kaplan R., Maughan T.S., et al. Does anti-EGFR therapy improve outcome in advanced colorectal cancer? A systematic review and meta-analysis. Cancer Treat Rev 2012, 38:618-625.
127. Kansal K.J., Dominici L.S., Tolaney S.M., Isakoff S.J., Krop I.E., Smith B.L., et al. Neoadjuvant bevacizumab: surgical complications of mastectomy with and without reconstruction. ASCO Meet Abstr 2013, 31:1100.
128. Kennecke H.F., Chen L., Blanke C.D., Cheung W.Y., Schaff K., Speers C. Panitumumab (Pmab) versus cetuximab (Cmab)/irinotecan (Iri) therapy among patients with KRAS wild-type (wt) metastatic colorectal cancer (MCRC). ASCO Meet Abstr 2012, 30:640.
129. Maughan T.S., Adams R.A., Smith C.G., Meade A.M., Seymour M.T., Wilson R.H., et al. Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial. Lancet 2011, 377:2103-2114.
130. Cheng A.-L., Cornelio G., Shen L., Price T., Yang T.-S., Chung I.-J., et al. First-line cetuximab with FOLFOX or FOLFIRI every 2 weeks in KRAS wild-type metastatic colorectal cancer: phase II APEC study. Ann Oncol 2013, 24(Suppl. 4).
131. Tveit K.M., Guren T., Glimelius B., Pfeiffer P., Sorbye H., Pyrhonen S., et al. Phase III trial of cetuximab with continuous or intermittent fluorouracil, leucovorin, and oxaliplatin (Nordic FLOX) versus FLOX alone in first-line treatment of metastatic colorectal cancer: the NORDIC-VII study. J Clin Oncol 2012, 30:1755-1762.
132. Prenen H., Vecchione L., Van Cutsem E. Role of targeted agents in metastatic colorectal cancer. Target Oncol 2013, 8:83-96.
133. Custodio A., Barriuso J., de Castro J., Martinez-Marin V., Moreno V., Rodriguez-Salas N., et al. Molecular markers to predict outcome to antiangiogenic therapies in colorectal cancer: Current evidence and future perspectives. Cancer Treat Rev 2013, 39:908-924.
134. Yang Z.Y., Wu X.Y., Huang Y.F., Di M.Y., Zheng D.Y., Chen J.Z., et al. Promising biomarkers for predicting the outcomes of patients with KRAS wild-type metastatic colorectal cancer treated with anti-epidermal growth factor receptor monoclonal antibodies: A systematic review with meta-analysis. Int J Cancer 2013, 133:1914-1925.
135. Misale S., Yaeger R., Hobor S., Scala E., Janakiraman M., Liska D., et al. Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer. Nature 2012, 486:532-536.
136. Diaz L.A., Williams R.T., Wu J., Kinde I., Hecht J.R., Berlin J., et al. The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers. Nature 2012, 486:537-540.
137. Dienstmann R., Tabernero J., Van Cutsem E., Cervantes-Ruiperez A., Rosello Keranen S., Benavent Vinuales M., et al. Proof-of-concept study of Sym004, an anti-EGFR monoclonal antibody (mAb) mixture, in patients (pts) with anti-EGFR mab-refractory KRAS wild-type (wt) metastatic colorectal cancer (mCRC). ASCO Meet Abstr 2013, 31:3551.
138. Prenen H., Vecchione L., Van Cutsem E. Role of targeted agents in metastatic colorectal cancer. Target Oncol 2013, 8:83-96.
139. Choi H., Charnsangavej C., Faria S.C., Macapinlac H.A., Burgess M.A., Patel S.R., et al. Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria. J Clin Oncol 2007, 25:1753-1759.